CYPH
Cypherpunk Technologies Inc.
There isn't enough reported data to score CYPH yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CYPH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CYPH's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CYPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.5x | $1.95 | — |
| Cheap | 3.7x | $2.09 | +7.4% |
| Fair | 5.4x | $3.00 | +54% |
| Forward | 5.6x | $1.95 | — |
| Expensive | 13x | $7.33 | +276% |
Historical ranges are pointers, not guarantees.
CYPH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CYPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CYPH to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CYPH on the outlook, with more favorable valuation expectations.
CYPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | -37% |
| Q2 2026 | $0.56 | +$2.11 |
| Q1 2026 | -$0.02 | +$1.65 |
| Q4 2025 | $0.07 | +$1.88 |
| Q3 2023 | -$5.72 | -$1.12 |
| Q2 2023 | -$6.51 | -$1.81 |
| Q1 2023 | -$7.10 | -$2.70 |
| Q4 2022 | -$4.80 | -$0.10 |
CYPH has returned to profit: it earned $0.56 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CYPH on earnings, with more consistent year-over-year improvement.
CYPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2021 | $375K | 0% |
| Q3 2021 | $375K | 0% |
| Q2 2021 | $375K | 0% |
| Q1 2021 | $375K | 0% |
LLY has the stronger quarterly revenue trend. Revenue is flat for CYPH versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | -2797% | -889 points |
| Q3 2021 | -3237% | -1235 points |
| Q2 2021 | -2567% | -568 points |
| Q1 2021 | -2446% | -744 points |
| Q4 2020 | -1908% | N/A |
| Q3 2020 | -2002% | N/A |
| Q2 2020 | -1999% | N/A |
| Q1 2020 | -1702% | N/A |
CYPH's operating margin was −2797% last quarter, down 889 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CYPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | +$11.8M |
| Q1 2026 | -$3.4M | +$11.1M |
| Q4 2025 | -$6.6M | +$8.9M |
| Q3 2025 | -$8.3M | +$7.3M |
| Q2 2025 | -$14.5M | -$815K |
| Q1 2025 | -$14.5M | +$1M |
| Q4 2024 | -$15.5M | -$5.1M |
| Q3 2024 | -$15.6M | -$5.1M |
CYPH has burned cash in almost every quarter: −$21M over the past year, against −$60M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CYPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +49.2M shares |
| 1 year | +427% | +176M shares |
| 3 years | +1819% | +206M shares |
| 5 years | +2748% | +210M shares |
CYPH has 217M diluted shares, up 427% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CYPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CYPH Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CYPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.7 | Neutral |
| Stochastic | 55.7 | Neutral |
CYPH's weekly RSI is 50 (neutral) and its Stochastic is 56 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CYPH PE vs Healthcare Sector
| Metric | CYPH | Sector median | Relative |
|---|---|---|---|
| PE | 3.5x | 26x | 87% below |
| PE % | 14 | 29 | 15 pts below |
CYPH has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CYPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.91 | 33% below |
| 20 week MA | $1.97 | 1% below |
| 50 week MA | $1.32 | 48% above |
| 100 week MA | $1.06 | 84% above |
| 200 week MA | $2.12 | 8% below |
CYPH's trend is mixed: it's above two of its five weekly moving averages, and 8% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CYPH on trend strength, trading above more of its moving averages.
CYPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.0 | $22.2 | +102% |
| 2021 | $22.2 | $29.5 | +33% |
| 2022 | $29.5 | $4.70 | -84% |
| 2023 | $4.70 | $4.14 | -12% |
| 2024 | $4.14 | $2.95 | -29% |
| 2025 | $2.95 | $1.20 | -59% |
| 2026 YTD | $1.20 | $1.95 | +63% |
CYPH has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.